InGel Therapeutics
InGel Therapeutics is a biotech company in Boston, United States, founded in 2022. It has raised $10.7M across 5 rounds, most recently a $1.4M Convertible Note in September 2025.
- Headquarters
- Boston
- Employees
- 1–10
- Founded
- 2022
- Business Model
- B2B
- Website
- ingeltx.com
- Total Funding
- $10.7M
- Last Round
- $1.4M Convertible NoteSep 2025
- Rounds
- 5
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 5 funding rounds for this company. The full record is or through the API.
About
InGel Therapeutics develops engineered cell therapy targeting neuroprotective pathways to treat retinal degeneration. Its approach includes a biomimetic hydrogel matrix that enables delivery of retinal neurons in vivo. The therapeutic development work focuses on neuroprotection in the context of retinal degeneration.
Summary
It lists 1–10 employees. It has raised $10.7M in total across 5 rounds, most recently a $1.4M Convertible Note round in Sep 2025.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sep 2025
Sign up to see all 5 events
Funding: Pre-Seed through Convertible Note. Amounts, valuations, and investors where available.
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/ingel-therapeutics"><img src="https://indexed.vc/api/badge/company/ingel-therapeutics" alt="InGel Therapeutics on Indexed.vc" width="260" height="76" /></a>